• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估一种新的 FGF23 全自动化学发光免疫分析法。

Evaluation of a new automated chemiluminescence immunoassay for FGF23.

机构信息

Division of Nephrology and Endocrinology, Department of Medicine, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

出版信息

J Bone Miner Metab. 2012 Mar;30(2):217-21. doi: 10.1007/s00774-011-0306-4. Epub 2011 Sep 7.

DOI:10.1007/s00774-011-0306-4
PMID:21898178
Abstract

Fibroblast growth factor 23 (FGF23) is a hormone regulating phosphate and vitamin D metabolism. We have previously established a sandwich enzyme-linked immunosorbent assay (ELISA) for FGF23 and reported that FGF23 values are useful for the differential diagnosis of chronic hypophosphatemia. However, this ELISA has a rather narrow assay range of 3-800 pg/ml, and it was pointed out that the assay performance is not satisfactory when automatic washing is used. Here we evaluated a new automated chemiluminescence immunoassay for FGF23. This assay uses 10 μl sera or plasma samples and requires 20 min to obtain the first result. The assay was linear up to about 15,000 pg/ml and had a detection limit of 1 pg/ml. In addition, this assay showed coefficients of variation of less than 5% using samples with average FGF23 levels of 43.2-2,454.0 pg/ml. When FGF23 levels in 210 samples from chronic hypophosphatemic patients were evaluated by both the previous ELISA and this new assay, there was a good correlation of R (2) = 0.96. However, FGF23 levels by the new assay showed lower values, especially in samples with high FGF23 levels. Given that the lowest FGF23 level in patients with FGF23-related hypophosphatemia was 30.8 pg/ml and that the highest FGF23 levels in patients with non-FGF23-related hypophosphatemia was 20.8 pg/ml by this novel assay, the sensitivity and specificity were 100% when the cutoff was set between 20.8 and 30.8 pg/ml. From the aspect of convenience and the coefficients of variation of this assay, we propose that the cutoff be 25 pg/ml. There results indicate that this new assay is ideal for both clinical use and clinical studies, especially when measuring many samples with high FGF23 levels.

摘要

成纤维细胞生长因子 23(FGF23)是一种调节磷酸盐和维生素 D 代谢的激素。我们之前建立了一种成纤维细胞生长因子 23 的夹心酶联免疫吸附测定法(ELISA),并报道 FGF23 值可用于慢性低磷血症的鉴别诊断。然而,这种 ELISA 的测定范围相当狭窄,为 3-800pg/ml,并且当使用自动洗涤时,其测定性能并不令人满意。在此,我们评估了一种新的自动化化学发光免疫分析法用于检测 FGF23。该测定法使用 10μl 血清或血浆样本,并且需要 20 分钟才能获得第一个结果。该测定法的线性范围约为 15,000pg/ml,检测限为 1pg/ml。此外,当使用平均 FGF23 水平为 43.2-2454.0pg/ml 的样本时,该测定法的变异系数小于 5%。当用之前的 ELISA 和新的测定法评估 210 例慢性低磷血症患者的 FGF23 水平时,两者的相关性良好(R2=0.96)。然而,新测定法的 FGF23 水平显示出较低的值,特别是在 FGF23 水平较高的样本中。鉴于 FGF23 相关低磷血症患者的最低 FGF23 水平为 30.8pg/ml,而非 FGF23 相关低磷血症患者的最高 FGF23 水平为 20.8pg/ml,因此,当将截断值设置在 20.8 和 30.8pg/ml 之间时,该测定法的灵敏度和特异性均为 100%。从该测定法的便利性和变异系数方面考虑,我们建议将截断值设置为 25pg/ml。这些结果表明,该新测定法既适用于临床应用,也适用于临床研究,特别是在测量具有高 FGF23 水平的大量样本时。

相似文献

1
Evaluation of a new automated chemiluminescence immunoassay for FGF23.评估一种新的 FGF23 全自动化学发光免疫分析法。
J Bone Miner Metab. 2012 Mar;30(2):217-21. doi: 10.1007/s00774-011-0306-4. Epub 2011 Sep 7.
2
Technical and diagnostic performance of a new fully automated immunoassay for the determination of intact fibroblast growth factor 23 (FGF23).一种用于测定完整成纤维细胞生长因子23(FGF23)的新型全自动免疫测定法的技术与诊断性能
Scand J Clin Lab Invest. 2018 Nov-Dec;78(7-8):584-590. doi: 10.1080/00365513.2018.1526411. Epub 2018 Oct 31.
3
Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system.新化学发光完整 FGF23 检测与现有检测系统的性能评估。
J Bone Miner Metab. 2022 Jan;40(1):101-108. doi: 10.1007/s00774-021-01258-7. Epub 2021 Aug 5.
4
Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.成纤维细胞生长因子23(FGF23)检测在低磷血症患者中的临床应用:基于FGF23检测的诊断标准建议
Bone. 2008 Jun;42(6):1235-9. doi: 10.1016/j.bone.2008.02.014. Epub 2008 Mar 5.
5
Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.评估一种新的全自动血浆完整成纤维细胞生长因子 23 检测方法。
Calcif Tissue Int. 2017 Nov;101(5):510-518. doi: 10.1007/s00223-017-0307-y. Epub 2017 Jul 31.
6
Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia.一种新型完整成纤维细胞生长因子23免疫测定法在健康个体和慢性低磷血症患者中的临床性能。
Bone Rep. 2023 Feb 2;18:101659. doi: 10.1016/j.bonr.2023.101659. eCollection 2023 Jun.
7
Serum FGF23 levels in normal and disordered phosphorus homeostasis.正常和紊乱的磷稳态中的血清成纤维细胞生长因子23水平。
J Bone Miner Res. 2003 Jul;18(7):1227-34. doi: 10.1359/jbmr.2003.18.7.1227.
8
Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.成纤维细胞生长因子23(FGF23)在肾移植术后即刻磷和钙代谢中的作用
Transplant Proc. 2012 Nov;44(9):2551-4. doi: 10.1016/j.transproceed.2012.09.070.
9
FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.静脉注射聚麦芽糖铁后FGF23升高与低磷血症:一项前瞻性研究。
J Clin Endocrinol Metab. 2009 Jul;94(7):2332-7. doi: 10.1210/jc.2008-2396. Epub 2009 Apr 14.
10
Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.日本全国范围内成纤维细胞生长因子23(FGF23)相关低磷性疾病的调查:患病率、生化数据及治疗情况
Endocr J. 2015;62(9):811-6. doi: 10.1507/endocrj.EJ15-0275. Epub 2015 Jul 1.

引用本文的文献

1
Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets.健康婴儿、儿童和青少年的完整 FGF23 浓度,以及在 X 连锁低磷性佝偻病患者中的诊断价值。
J Endocrinol Invest. 2024 Apr;47(4):873-882. doi: 10.1007/s40618-023-02202-4. Epub 2023 Nov 22.
2
Normocalcemic primary hyperparathyroidism is an early stage of primary hyperparathyroidism according to fibroblast growth factor 23 level.根据成纤维细胞生长因子 23 水平,血钙正常的甲状旁腺功能亢进症是甲状旁腺功能亢进症的早期阶段。
Front Endocrinol (Lausanne). 2023 Mar 30;14:1152464. doi: 10.3389/fendo.2023.1152464. eCollection 2023.
3

本文引用的文献

1
FGF-23 as a predictor of renal outcome in diabetic nephropathy.成纤维细胞生长因子 23 可预测糖尿病肾病的肾脏结局。
Clin J Am Soc Nephrol. 2011 Feb;6(2):241-7. doi: 10.2215/CJN.04250510. Epub 2010 Oct 21.
2
Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men.血清成纤维细胞生长因子 23(FGF-23)与老年男性骨折风险。
J Bone Miner Res. 2011 Apr;26(4):857-64. doi: 10.1002/jbmr.263.
3
Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.成纤维细胞生长因子23的体静脉采样在识别肿瘤性骨软化症相关肿瘤中的临床应用
Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia.
一种新型完整成纤维细胞生长因子23免疫测定法在健康个体和慢性低磷血症患者中的临床性能。
Bone Rep. 2023 Feb 2;18:101659. doi: 10.1016/j.bonr.2023.101659. eCollection 2023 Jun.
4
Determination of iFGF23 Upper Reference Limits (URL) in healthy pediatric population, for its better correct use.确定健康儿科人群中 iFGF23 的上参考限值 (URL),以更好地正确使用。
Front Endocrinol (Lausanne). 2022 Nov 9;13:1018523. doi: 10.3389/fendo.2022.1018523. eCollection 2022.
5
Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.测定 FGF23 水平以诊断 FGF23 介导的低磷血症。
J Bone Miner Res. 2022 Nov;37(11):2174-2185. doi: 10.1002/jbmr.4702. Epub 2022 Oct 17.
6
Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease.成纤维细胞生长因子-23在慢性肾脏病矿物质骨病中的诊断效用
J Circ Biomark. 2022 Jan 8;11:1-4. doi: 10.33393/jcb.2022.2328. eCollection 2022 Jan-Dec.
7
Assessment of the measurement of canine and feline serum fibroblast growth factor-23 concentrations by automated chemiluminescence immunoassay.应用自动化化学发光免疫分析法评估犬和猫血清成纤维细胞生长因子 23 浓度的测定。
J Vet Med Sci. 2022 Feb 23;84(2):257-260. doi: 10.1292/jvms.21-0566. Epub 2021 Dec 30.
8
FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.成纤维细胞生长因子 23:在矿物质代谢及肾脏和心血管疾病中的作用综述。
Dis Markers. 2021 May 17;2021:8821292. doi: 10.1155/2021/8821292. eCollection 2021.
9
Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study.日本透析结果与实践模式研究中,成纤维细胞生长因子23与维持性血液透析患者死亡率的关系
Kidney Int Rep. 2020 Aug 20;5(11):1956-1964. doi: 10.1016/j.ekir.2020.08.013. eCollection 2020 Nov.
10
Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study.透析患者红细胞生成素抵抗与成纤维细胞生长因子 23 的相关性:来自日本透析结局和实践模式研究的结果。
Nephrology (Carlton). 2021 Jan;26(1):46-53. doi: 10.1111/nep.13765. Epub 2020 Aug 20.
J Intern Med. 2010 Oct;268(4):390-4. doi: 10.1111/j.1365-2796.2010.02262.x.
4
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.FGF23 的 C 端尾部可通过抑制 FGF23-FGFR-Klotho 复合物的形成来缓解低磷血症。
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):407-12. doi: 10.1073/pnas.0902006107. Epub 2009 Dec 4.
5
Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies.比较化学发光酶免疫分析(CLEIA)与酶联免疫吸附试验(ELISA)测定抗环瓜氨酸肽抗体。
Clin Chim Acta. 2010 Jan;411(1-2):22-5. doi: 10.1016/j.cca.2009.09.032. Epub 2009 Oct 7.
6
Determination of fibroblast growth factor 23.成纤维细胞生长因子23的测定
Ann Clin Biochem. 2009 Jul;46(Pt 4):338-40. doi: 10.1258/acb.2009.009066. Epub 2009 Jun 29.
7
Bone as an endocrine organ.骨骼作为一个内分泌器官。
Trends Endocrinol Metab. 2009 Jul;20(5):230-6. doi: 10.1016/j.tem.2009.02.001. Epub 2009 Jun 21.
8
Relationship between circulating FGF23 and total body atherosclerosis in the community.社区中循环成纤维细胞生长因子23(FGF23)与全身动脉粥样硬化的关系。
Nephrol Dial Transplant. 2009 Oct;24(10):3125-31. doi: 10.1093/ndt/gfp205. Epub 2009 May 9.
9
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.成纤维细胞生长因子23与慢性肾脏病左心室肥厚
Circulation. 2009 May 19;119(19):2545-52. doi: 10.1161/CIRCULATIONAHA.108.844506. Epub 2009 May 4.
10
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.成纤维细胞生长因子23与接受血液透析患者的死亡率
N Engl J Med. 2008 Aug 7;359(6):584-92. doi: 10.1056/NEJMoa0706130.